Slide 1: 2012 Financial Results & Business Update
2012 Financial Results & Business Update Stock Code: 00853(HK) March 2013
Slide 2: Content
Content 2012 Financial Results Business Update Company Vision & Strategic Plans *Appendix - Financial Statements Unsaved Document / 2/25/2010 / 2:14 PM 1
Slide 3: Financial Summary 2012
Financial Summary 2012 Highlights Key Financial Summary Revenue: 931m, Y/Y ↑10.8% RMB: million 2012 2011 Flux Revenue 931.0 839.8 10.8% Net profit: 354m ,Y/Y ↑10.3% Cost (153.1) (137.3) 11.6% Completion of Key Clinical Trial: Gross Profit 777.8 702.6 10.7% Expenses (423.4) (403.1) 5.0% The clinica
Slide 4: Solid Financial Performance
Solid Financial Performance Revenue & Gross Margin Net Profit & Net Margin (RMB million) (RMB million) 5Y CAGR: 18% 5Y CAGR: 19% 86% 87% 84% 84% 82% 38% 38% 37% 33% 33% 931.0 839.8 727.7 560.7 354.0 320.9 485.2 240.1 186.4 Unsaved Document / 2/25/2010 / 2:14 PM 178.8 2008 2009 2010 2011 2012 2008 20
Slide 5: Business Diversification: Revenue Mix for Reference
Business Diversification —— Revenue Mix for Reference Revenue by Products (Year 2012) Other cardiovascular Endovascular devices, devices, 4.0% Diabetes care and 7.2% (67M) endocrinal Management, Neurovascular devices, 1.0% 2.2% (21M) Electrophysiology devices, 1.0% New Surgical devices, business, 1.
Slide 6: Operating Expenses
Operating Expenses Sales and Marketing Cost Administrative Expense Research and Development Cost (RMB million) (RMB million) (RMB million) 18.1% 18.6% 17.5% 17.7% 18.2% 13.6% 16.2% 15.7% 15.4% 11.7% 11.2% 12.2% 9.9% 9.6% 9.1% 173.0 152.1 129.0 104.6 153.0 145.8 98.2 97.9 117.9 66.2 69.7 86.4 48.1 50
Slide 7: Business Update
Business Update 1 Vascular Business 2 Electrophysiology Business 3 Orthopedics Business 4 Diabetes and Endocrinal Devices 5 Surgical Management – Dongguan Kewei Unsaved Document / 2/25/2010 / 2:14 PM 6 Long-Term R&D Pipeline 6
Slide 8: Vascular Business: DES Market Leader with Strong Brand Recognition
1-1 Vascular Business DES-Market Leader with Strong Brand Recognition DES Market Leadership (2012) DES Revenue (2008-2012) RMB: million (in terms of units implanted) 729.3 741.7 627.8 ≈ 75% 484.1 30% 421.7 20% 10% Unsaved Document / 2/25/2010 / 2:14 PM 0% Lepu Jiwei Others Abbot Medtronic Boston 200
Slide 9: DES Firehawk R&D Status
1-1 Vascular Business DES-Firehawk R&D Status Firebird 2 Firehawk Clinical Trial Phase 1 First in Man (“FIM”) (Completed) Commercially launched in Third generation DES January 2009 Phase 2 Cobalt-chromium target-eluting TARGET I Constructed of cobalt- stent coated with sirolimus A study of r
Slide 10: Endovascular – Stent Graft
1-2 Vascular Business Endovascular – Stent Graft TAA/AAA Market Leadership (2012) Products Profile (in terms of units implanted) Castor Branched Aortic Stent-Graft and Delivery System 30% Clinical Trial to be kicked off in 2012 20% Hercules B / Hercules T 10% 0% Medtronic Metronic Cook Others Un
Slide 11: Neurovascular – Apollo, Willis
1-3 Vascular Business Neurovascular – Apollo, Willis Solid Growth of Apollo in Revenue Products Already Received SFDA Approval RMB: million Willis 20.8 17.5 13.4 Intracranial Stent Graft System 8.6 Received SFDA approval on March, 2013 2.6 2008 2009 2010 2011 2012 Leading Position in Neurovascul
Slide 12: Electrophysiology Business
2 Electrophysiology Business Solid Growth of Electrophysiology in Revenue R&D Pipeline RMB: million 9.7 Columbus 5.5 3D Mapping System Clinical Trial in 2012 1.5 2010 2011 2012 Products on the Market Voyager Unsaved Document / 2/25/2010 / 2:14 PM Irrigated RF Ablation Cathete Clinical Trial
Slide 13: Orthopedics Business
3 Orthopedics Business Milestones Sales Split by Application Key Factors 2009 • Established Shanghai Other MicroPort Orthopedics Spine RMB:33M 2010 Trauma Employee: 180 in total • Obtained CE Certificates Facilities: increase an area of 11,000㎡ for over 5 products since Certificates: over 20 d
Slide 14: Diabetes and Endocrinal Devices Business
4 Diabetes and Endocrinal Devices Business Solid Growth of Diabetes Business in Revenue Products Profile RMB: million Micro-Infusion GnRH Pump (Artificial Pituitary Pump) 9.7 Innovative Solution for Hypogonadotropic Hypogonadism (HH) Contribute a lot to the revenue 2.8 2011 2012 R&D Pipeline La
Slide 15: Surgical Devices Business
5 Surgical Devices Business Key Factors Oxygenators Market Leadership Kewei 22% 15% Medtronic Terumo Medos AG 14% Sorin 12% • Located on Dongguan, Guangdong province Jostra AG 10% • 28 patents in China Xijian Medical 8% • Around 160 employees, over 20 engineers and 10 sales 10% Others 9% • Products
Slide 16: Long-Term R&D Pipeline
6 Long-Term R&D Pipeline (over 5 years) Pacemaker & Pacing Lead Others IPG (Implantable Pulse Generator) Transcatheter Aortic Valve Implantation system Under R&D stage Under R&D stage （微创医芯） Pacing Leads Intramyocardial injection – active & passive catheter Under R&D stage Under R&D stage Un
Slide 17: Company Vision & Long-Term Strategic Plans
Unsaved Document / 2/25/2010 / 2:14 PM Cardiovascular Endovascular & Peripheral vascular Neurovascular Endo Surgery General Surgery Electrophysiology Long-Term Strategic Plans: 10+5 Cardiac Rhythm Management Orthopedics Diabetes and Endocrinal Devices TBD Company Vision & Long-Term Strategic Plans C
Slide 18: Appendix I - Consolidated Income Statement
Appendix I - Consolidated Income Statement (RMB '000) 2012 Actual 2011 Actual Revenue 930,962 839,849 Cost of sales (153,129) (137,268) Gross profit 777,833 702,581 Other revenue & net income 67,898 93,827 Research and development costs (145,849) (153,035) Sales and marketing costs (172,999) (152,11
Slide 19: Appendix II - Consolidated Balance Sheet
Appendix II - Consolidated Balance Sheet RMB'000 31 Dec 2012 31 Dec 2011 Cash and cash equivalents 413,149 1,095,209 Deposits with banks 666,275 319,279 Trade & Other receivables 433,890 286,617 Inventories 92,654 73,962 Total current assets 1,605,968 1,775,067 Fixed Assets & CIP & Prepay for FA 720
Slide 20: Appendix III - Condensed Consolidated Cash Flow Statement
Appendix III - Condensed Consolidated Cash Flow Statement - Adjusted * (RMB '000) 2012 Actual 2011 Actual Cash generate from operations 352,250 364,339 Income tax paid (66,664) (64,209) Net cash generated from operating activities 285,586 300,130 Net cash (used in)/from investing activities (460,867
Slide 21: Disclaimer
Disclaimer This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of,
Slide 22: Thank You
Unsaved Document / 2/25/2010 / 2:14 PM Thank You 21